<DOC>
	<DOCNO>NCT02225548</DOCNO>
	<brief_summary>The purpose study see selegiline tadalafil ( generic Cialis® ) result improvement Erectile dysfunction ( ED ) male patient Parkinson 's disease ( PD ) moderate ED . Male PD patient incomplete response tadalafil alone give medication see addition selegiline improve ED symptom tadalafil alone . It common practice medical doctor prescribe two drug patient like . However , study conduct examine effect medication take together . Selegiline normally prescribe PD patient take carbidopa/levodopa receive complete benefit carbidopa/levodopa . Tadalafil normally prescribe men erectile dysfunction and/or benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Sagene 2014 - Parkinson 's Disease Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Inclusion Criteria Diagnosis idiopathic Parkinson 's disease optimally treat ( motor fluctuation &lt; 20 % subject 's awake time ) . Subjects may levodopa therapy must stable time entry study Sexually active ( i.e . ≥1 attempt/week ) male , 40 64 year age ( inclusive ) time screen Diagnosis moderate erectile dysfunction ( define accord NIH Consensus Development Panel Impotence ) 6 month demonstrate incomplete response tadalafil alone Subject demonstrate IIEF5 drugfree baseline score ≥ 10 ≤ 16 , IIEF5 tadalafilalone baseline score ≤ 18 Subject stable heterosexual relationship least 6 month . ( 2 ) Subject motivate seek treatment erectile dysfunction . Subject total serum testosterone level ≥ 300 ng/dL , without supplementation Hoehn Yahr Scale score 1 3 Patient able consent comply protocol requirement Subject unwilling cease use treatment erectile dysfunction study , include oral medication , vacuum device , constrictive device , injection , urethral suppository , gel , overthecounter nonprescription medication , product purchase via internet Subject receive dopamine agonist , nitrate , alphareceptor block agent , antihypertensive medication ( see exclusionary medication list ) Subject history syncope within last 6 month prior screen Subject symptomatic postural hypotension ( severe dizziness fainting Subject hypotension rest systolic blood pressure &lt; 90 mmHG hypertension rest systolic blood pressure &gt; 170 mmHG rest diastolic blood pressure &gt; 110 mmHG Subject underlie cardiovascular condition , include unstable angina pectoris , preclude sexual activity Subject history myocardial infarction , stroke lifethreatening arrhythmia within 6 month prior screen Subject uncontrolled atrial fibrillation/flutter screening ( defined ventricular response rate ≥ 100 bpm ) Subject bleed disorder Subject history prostatectomy prostate cancer , include nerve spar technique . Subjects history surgical procedure treatment benign prostate hypertrophy permit , exception cryosurgery , cryotherapy cryoablation Subject hereditary degenerative retinal disorder retinitis pigmentosa Subject history loss vision nonarteritic anterior ischemic optic neuropathy ( NAION ) , history temporary permanent loss vision , include unilateral loss vision Subject history congenital QT prolongation Subject penile anatomical abnormality ( e.g. , penile fibrosis , fracture , Peyronie 's disease ) , investigator 's opinion , could significantly impair sexual performance . This base subject 's reported medical history ( penile exam require ) Subject primary hypoactive sexual desire . Subject spinal cord injury Subject severe chronic acute liver disease , history moderate ( ChildPugh B ) , severe ( ChildPugh C ) hepatic impairment Subject clinically significant chronic hematological disease could lead priapism sickle cell anemia , multiple myeloma , leukemia Subject active peptic ulceration Subject history malignancy within past 5 year ( squamous basal cell skin cancer ) Subject history positive test Hepatitis B surface antigen ( HbsAg ) Hepatitis C Subject know hypersensitivity component investigational medication , monoamine oxidase inhibitor , phosphodiesterase type 5 inhibitor phenylethylamines Subjects history drug alcohol abuse within past 6 month Subjects currently consume ≥5 unit alcohol per day Subject illiterate unable understand Informed Consent Form , questionnaires subject diary Subject , opinion investigator , noncompliant visit schedule study procedure Subject unstable medical , psychiatric , substance abuse disorder opinion investigator likely affect subject 's ability complete study preclude subject 's participation study Diagnosis neurologic disease Uncontrolled Diabetes ( Hemoglobin A1C &gt; 7.5 )</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>